STOCKHOLM, July 16, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter of 2026.

Second Quarter 2026

Total revenue increased 29 per cent at CER (constant exchange rates), 27 per cent at actual rates, to SEK 7,842 M (6,175)
Haematology revenue increased 27 per cent at CER to SEK 5,726 M (4,570), mainly driven by strong sales of Altuvoct of SEK 1,554 M (627) and of Doptelet of SEK 1,628 M (1,220)
Immunology revenue increased 37 per cent at CER to SEK 1,711 M (1,288), driven by strong sales of Gamifant of SEK 794 M (632) and Kineret of SEK 861 M (749)
Revenue from the strategic portfolio¹ grew by 53 per cent at CER to SEK 5,095 M (3,384)
The adjusted EBITA margin^1,2 was 35 per cent (34), excluding IAC² of SEK 355 M (237). EBITA¹ was SEK 2,843 M (1,863), corresponding to a margin of 36 per cent (30). EBIT was SEK 1,627 M (1,010)
Earnings per share (EPS) before dilution was SEK 3.17 (1.85) and EPS after dilution was SEK 3.14 (1.83). Adjusted EPS before dilution¹ was SEK 4.00 (2.38) and adjusted EPS after dilution¹ was SEK 3.96 (2.36)
Cash flow from operating activities was SEK 1,912 M (1,448)
NASP: Complete Response Letter (CRL) received on manufacturing with a clear path to resubmission for the potential treatment of uncontrolled gout
Pozdeutinurad: Positive topline results from the pivotal Phase 3 REDUCE 2 study in gout

Outlook 2026 - Updated

Revenue is anticipated to grow by a mid-to high-teens percentage at CER (previously low double-digit)
The adjusted EBITA margin is anticipated to be in the mid-to high-30s percentage of revenue (previously mid 30s)

1. Alternative Performance Measures (APMs).
2. Items affecting comparability (IAC).

Investors, analysts, and the media are invited to a conference call on the same day at 14:00 CEST, 13:00 BST, and 08:00 EDT. The call will include a presentation of the results and a Q&A session.

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.

To participate in the conference call, please use the following dial-in details:

HD Web Phone™: click here

Sweden: +46 8 5051 0031
United Kingdom: +44 203 059 58 63
United States: +1 631 570 56 13

For other countries, please find the details here.

Sobi®

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication through the agency of the contact person set out below on 16 July 2026 at 08:00 CEST.

Gerard Tobin
Head of Investor Relations

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-q2-2026-report--significant-growth-with-important-pipeline-progress,c4375126

The following files are available for download:


 
 https://mb.cision.com/Main/14266/4375126/4194029.pdf Q2 2026 report.Significant growth with important
                                                          pipeline progress

View original content:https://www.prnewswire.co.uk/news-releases/sobi-q2-2026-report-significant-growth-with-important-pipeline-progress-302827274.html

Tags

More Like This

Sobi Q1 2026 report: Strong execution and pipeline momentum

Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum

Sobi Q3 2024 report: Strong growth and significant pipeline momentum

Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance

Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress

Sobi publishes Q1 2025 report: Portfolio continues to deliver

Sobi Q3 2025 report: Accelerated growth and portfolio momentum

Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024